Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Tarantino, Paolo; Ricciuti, Biagio; Pradhan, Shan M.; Tolaney, Sara M.

doi:10.1038/s41571-023-00783-w

Cited by 269Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Tarantino, Paolo, Ricciuti, Biagio, Pradhan, Shan M., Tolaney, Sara M.·2023·Nature Reviews Clinical Oncology

DOI 10.1038/s41571-023-00783-w

Open this paper in CoChat — free account

Abstract

Over the past 5 years, improvements in the design of antibody-drug conjugates (ADCs) have enabled major advances that have reshaped the treatment of several advanced-stage solid tumours. Considering the intended rationale behind the design of ADCs, which is to achieve targeted delivery of cytotoxic molecules by linking them to antibodies targeting tumour-specific antigens, ADCs would be expected to be less toxic than conventional chemotherapy. However, most ADCs are still burdened by off-target toxicities that resemble those of the cytotoxic payload as well as on-target toxicities and other poorly understood and potentially life-threatening adverse effects. Given the rapid expansion in the clinical indications of ADCs, including use in curative settings and various combinations, extensive efforts are ongoing to improve their safety. Approaches currently being pursued include clinical trials optimizing the dose and treatment schedule, modifications of each ADC component, identification of predictive biomarkers for toxicities, and the development of innovative diagnostic tools. In this Review, we describe the determinants of the toxicities of ADCs in patients with solid tumours, highlighting key strategies that are expected to improve tolerability and enable improvements in the treatment outcomes of patients with advanced-stage and those with early stage cancers in the years to come.

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00783-w

Cites

200 of 200 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ADCs were designed to improve the therapeutic index of cytotoxic agents by using monoclonal antibodies to enhance tumor cell selection.
“By using mAbs to enhance tumor cell selection, ADCs were designed to improve the therapeutic index of cytotoxic agents6,7.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [7]
Linker instability and side effects from systemic exposure to ADC payloads remain a significant challenge, with off-target and on-target toxicities frequently resembling those of unconjugated cytotoxic agents.
“However, clinical experience has shown that linker instability and side effects from systemic exposure to ADC payloads remain a significant challenge, with both off-target and on-target toxicities frequently resembling those of the unconjugated cytotoxic agents6,7.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [7]
Antibody-drug conjugates have substantial toxicity, primarily affecting the bone marrow.
“their substantial toxicity (primarily affecting the bone marrow) must be considered.69 70”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [70]

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777 · see citing works
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · see citing works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M. J., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,764 · see citing works
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiß, A., Redondo, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,649 · see citing works
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711 · see citing works
Self-citation
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,677 · see citing works
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643 · see citing works
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R. A., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,455 · see citing works
Self-citation
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,417 · see citing works
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349 · see citing works
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333 · see citing works
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,257 · see citing works
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J. S., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,254 · see citing works
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T. B., Rosenberg, J. E., Sonpavde, G., Loriot, Y., Durán, I., Lee, J., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,248 · see citing works
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,175 · see citing works
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854 · see citing works
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E. P., Tolaney, S. M., Cortés, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 804 · see citing works
Self-citation
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno‐Aspitia, A., Doi, T., Sagara, Y., Redfern, C. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 788 · see citing works
Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K. J. M., Shostak, Y., Raitano, A. B., Nadell, R., Liu, W. J., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 737 · see citing works
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Hurvitz, S. A., Hegg, R., Chung, W., Im, S., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E. P., Madhusudan, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 714 · see citing works
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro‐Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 658 · see citing works
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646 · see citing works
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 550 · see citing works
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F. C., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C. D., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 545 · see citing works
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543 · see citing works
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Junttila, T. T., Li, G., Parsons, K. L., Phillips, G. D. L., & Sliwkowski, M. X. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 539 · see citing works
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Hurvitz, S. A., Martín, M., Symmans, W. F., Jung, K. H., Huang, C., Thompson, A. M., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H. P. M. W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30716-7 · Cited by 538 · see citing works
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 499 · see citing works
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial
Morton, D. G., Seymour, M., Magill, L., Handley, K., Glasbey, J. C., Glimelius, B. L. G., Palmer, A., Seligmann, J. F., Laurberg, S., Murakami, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00046 · Cited by 473 · see citing works
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 443 · see citing works
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441 · see citing works
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier, P. R., Bugat, R., Douillard, J., Culine, S., Suc, E., Brunet, P., Bécouarn, Y., Ychou, M., Marty, M. E., Extra, J.-M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434 · see citing works
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Coleman, R. L., Lorusso, D., Gennigens, C., González-Martı́n, A., Randall, L. M., Cibula, D., Lund, B., Woelber, L. L., Pignata, S., Forget, F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00056-5 · Cited by 419 · see citing works
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Bardia, A., Messersmith, W. A., Kio, E. A., Berlin, J. D., Vahdat, L. T., Masters, G. A., Moroose, R. L., Santin, A. D., Kalinsky, K. M., Picozzi, V. J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.005 · Cited by 412 · see citing works
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Matulonis, U. A., Lorusso, D., Oaknin, A., Pignata, S., Dean, A. P., Denys, H. G., Colombo, N., Gorp, T. V., Konner, J. A., Romeo, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01900 · Cited by 401 · see citing works
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Pestana, R. C., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortés, J., Soria, J., & Curigliano, G. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 396 · see citing works
Self-citation
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 395 · see citing works
Tumor Localization of Radio-Labeled Antibodies against Carcinoembryonic Antigen in Patients with Carcinoma
Mach, J., Carrel, S., Forni, M., Ritschard, J., Donath, A., & Alberto, P. (1980) · New England Journal of Medicine · doi:10.1056/nejm198007033030102 · Cited by 393 · see citing works
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Emens, L. A., Esteva, F. J., Beresford, M. J., Saura, C., Laurentiis, M. D., Kim, S., Im, S., Wang, Y., Salgado, R., Mani, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30465-4 · Cited by 389 · see citing works
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C. H., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 353 · see citing works
Therapeutic targeting of EPH receptors and their ligands
Boyd, A., Bartlett, P. F., & Lackmann, M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4175 · Cited by 340 · see citing works
The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer
Toffoli, G., Cecchin, E., Corona, G., Russo, A. G., Buonadonna, A., D'Andrea, M. R., Pasetto, L. M., Pessa, S., Errante, D., Manzini, V. D. P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5400 · Cited by 337 · see citing works
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Advani, A. S., Coiffier, B., Czuczman, M. S., Dreyling, M. H., Foran, J. M., Giné, E., Gisselbrecht, C., Ketterer, N., Nasta, S. D., Rohatiner, A. Z. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336 · see citing works
A general approach to site-specific antibody drug conjugates
Tian, F., Lu, Y., Manibusan, A., Sellers, A. J., Tran, H., Sun, Y., Phuong, T., Barnett, R. S., Hehli, B., Song, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321237111 · Cited by 321 · see citing works
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
Yamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23793-7 · Cited by 318 · see citing works
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Kantarjian, H. M., Thomas, D. A., Jorgensen, J. L., Kebriaei, P., Jabbour, E. J., Rytting, M., York, S., Ravandi, F., Garris, R. E., Kwari, M. I., et al. (2013) · Cancer · doi:10.1002/cncr.28136 · Cited by 306 · see citing works
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Hoimes, C. J., Flaig, T. W., Milowsky, M. I., Friedlander, T. W., Bilen, M. A., Gupta, S., Srinivas, S., Merchan, J. R., McKay, R. R., Petrylak, D. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01643 · Cited by 289 · see citing works
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
Powell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J. C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100554 · Cited by 288 · see citing works
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286 · see citing works
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms.
Epenetos, A. A., Snook, D. E., Durbin, H., Johnson, P. M., & Taylor‐Papadimitriou, J. (1986) · PubMed · Cited by 284 · see citing works
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Blackhall, F. H., Jao, K., Greillier, L., Cho, B. C., Penkov, K., Reguart, N., Majem, M., Nackaerts, K., Syrigos, K., Hansen, K. H., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.009 · Cited by 282 · see citing works
Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates
Sun, X., Ponte, J. F., Yoder, N. C., Laleau, R., Coccia, J. A., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M. E., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00062 · Cited by 281 · see citing works
Progress in adjuvant systemic therapy for breast cancer
Ponde, N. F., Zardavas, D., & Piccart, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 275 · see citing works
Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
Stepan, L. P., Trueblood, E. S., Hale, K., Babcook, J. S., Borges, L., & Sutherland, C. L. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410430 · Cited by 273 · see citing works
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Norsworthy, K. J., Ko, C., Lee, J. E., Liu, J., John, C. S., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0604 · Cited by 271 · see citing works
Payload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257 · see citing works
Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252 · see citing works
Breast and prostate cancer: more similar than different
Risbridger, G. P., Davis, I. D., Birrell, S. N., & Tilley, W. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2795 · Cited by 248 · see citing works
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Nicolò, E., Giugliano, F., Ascione, L., Tarantino, P., Corti, C., Tolaney, S. M., Cristofanilli, M., & Curigliano, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102395 · Cited by 243 · see citing works
Self-citation
Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer
Meredith, K. L., Weber, J., Turaga, K. K., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0862-1 · Cited by 234 · see citing works
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
Shi, F., Liu, Y., Zhou, X., Shen, P., Xue, R., & Zhang, M. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2069883 · Cited by 225 · see citing works
Polatuzumab Vedotin: First Global Approval
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01175-0 · Cited by 222 · see citing works
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B., Du, X., Saad, O. M., Bowles, K. H., Olsen, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 220 · see citing works
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Yardley, D. A. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/137414 · Cited by 216 · see citing works
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
Tarantino, P., Jin, Q., Tayob, N., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2286 · Cited by 210 · see citing works
Self-citation
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Colombo, R., & Rich, J. R. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.016 · Cited by 200 · see citing works
Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y–Expressing Epithelial Tumors
Saleh, M. N., Sugarman, S., Murray, J. H., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 197 · see citing works
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192 · see citing works
Bystander effect of antibody–drug conjugates: fact or fiction?
Giugliano, F., Corti, C., Tarantino, P., Michelini, F., & Curigliano, G. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01266-4 · Cited by 190 · see citing works
Self-citation
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
Giordano, S. H., Franzoi, M. A., Temin, S., Anders, C. K., Chandarlapaty, S., Crews, J. R., Kirshner, J. J., Krop, I. E., Lin, N., Morikawa, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00519 · Cited by 188 · see citing works
Stepping forward in antibody-drug conjugate development
Jin, Y., Schladetsch, M. A., Huang, X., Balunas, M. J., & Wiemer, A. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107917 · Cited by 187 · see citing works
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Autio, K. A., Boni, V., Humphrey, R. W., & Naing, A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1457 · Cited by 184 · see citing works
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
Tarantino, P., Modi, S., Tolaney, S. M., Cortés, J., Hamilton, E. P., Kim, S., Toi, M., André, F., & Curigliano, G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3595 · Cited by 176 · see citing works
Self-citation
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2‐targeting Ab–drug conjugate, in monkeys
Kumagai, K., Aida, T., Tsuchiya, Y., Kishino, Y., Kai, K., & Mori, K. (2020) · Cancer Science · doi:10.1111/cas.14686 · Cited by 175 · see citing works
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac173 · Cited by 174 · see citing works
Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Andreev, J., Thambi, N., Bay, A. E. P., Delfino, F. J., Martin, J. W., Kelly, M. P., Kirshner, J. R., Rafique, A., Kunz, A., Nittoli, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0658 · Cited by 167 · see citing works
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2 -Positive Metastatic Breast Cancer
Borges, V. F., Ferrario, C., Aucoin, N., Falkson, C. I., Khan, Q. J., Krop, I. E., Welch, S. A., Conlin, A. K., Chaves, J. M., Bedard, P. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1812 · Cited by 162 · see citing works
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Rivera, E., & Cianfrocca, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2607-5 · Cited by 159 · see citing works
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
Liu, X., Cheng, D., Kuang, Q., Liu, G., & Xu, W. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.10 · Cited by 155 · see citing works
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET
Harbeck, N., Gluz, O., Christgen, M., Kates, R. E., Braun, M., Küemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9815 · Cited by 153 · see citing works
Improving target cell specificity using a novel monovalent bispecific IgG design
Mazor, Y., Oganesyan, V., Yang, C., Hansen, A. M., Wang, J., Liu, H., Sachsenmeier, K. F., Marcia, C., Gadre, D., Borrok, M. J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007816 · Cited by 150 · see citing works
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
O’Malley, D. M., Matulonis, U. A., Birrer, M. J., Castro, C. M., Gilbert, L., Vergote, I. B., Martin, L. P., Mantia-Smaldone, G. M., González-Martı́n, A., Bratos, R., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.037 · Cited by 149 · see citing works
Phase 1 dose‐escalation study of mirvetuximab soravtansine ( IMGN853 ), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors
Moore, K. N., Borghaei, H., O’Malley, D. M., Jeong, W., Seward, S. M., Bauer, T. M., Perez, R. P., Matulonis, U. A., Running, K. L., Zhang, X., et al. (2017) · Cancer · doi:10.1002/cncr.30736 · Cited by 144 · see citing works
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney, S. M., Tayob, N., Dang, C. T., Yardley, D. A., Isakoff, S. J., Valero, V., Faggen, M. G., Mulvey, T. M., Bose, R., Hu, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03398 · Cited by 141 · see citing works
Self-citation
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
de Goeij, B. E. C. G., Vink, T., ten Napel, H., Breij, E. C. W., Satijn, D. P. E., Wubbolts, R., Miao, D., & Parren, P. W. H. I. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0364 · Cited by 138 · see citing works
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Marei, H. E. S., Cenciarelli, C., & Hasan, A. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02679-8 · Cited by 138 · see citing works
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
Mamounas, E. P., Untch, M., Mano, M. S., Huang, C., Geyer, C. E., von Minckwitz, G., Wolmark, N., Pivot, X. B., Küemmel, S., DiGiovanna, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.011 · Cited by 130 · see citing works
Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Yamaguchi, K., Bang, Y., Iwasa, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00575 · Cited by 130 · see citing works
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Annunziata, C. M., Kohn, E. C., LoRusso, P. M., Houston, N. D., Coleman, R. L., Buzoianu, M., Robbie, G. J., & Lechleider, R. J. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9801-2 · Cited by 121 · see citing works
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
Lucas, A. T., Price, L., Schorzman, A. N., Storrie, M., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2018) · Antibodies · doi:10.3390/antib7010010 · Cited by 120 · see citing works
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Dieras, V. C., Carey, L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00467-1 · Cited by 117 · see citing works
Self-citation
Beyond thrombosis: the impact of tissue factor signaling in cancer
Unruh, D. J., & Horbinski, C. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00932-z · Cited by 117 · see citing works
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 115 · see citing works
Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
Rugo, H. S., Bardia, A., Marmé, F., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.17_suppl.lba1001 · Cited by 115 · see citing works
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
Schmid, P., Im, S., Armstrong, A. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.1023 · Cited by 114 · see citing works
Site-Specific Antibody Conjugation for ADC and Beyond
Zhou, Q. (2017) · Biomedicines · doi:10.3390/biomedicines5040064 · Cited by 107 · see citing works
Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
Kopp, A., Hofsess, S. J., Cardillo, T. M., Govindan, S. V., Donnell, J., & Thurber, G. M. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0375 · Cited by 106 · see citing works
Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma
Wei, C., Zhang, G., Clark, T. H., Barletta, F., Tumey, L. N., Rago, B., Hansel, S. B., & Han, X. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b00976 · Cited by 105 · see citing works
LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
Saura, C., O’Shaughnessy, J., Aftimos, P. G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2088 · Cited by 104 · see citing works
RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
Wang, J., Liu, Y., Zhang, Q., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.1022 · Cited by 104 · see citing works
Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Menzies, A. M., Rozeman, E. A., Amaria, R. N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9503 · Cited by 103 · see citing works
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot, H. C., McElroy, E., Reid, J. M., Windebank, A. J., Sloan, J. A., Erlichman, C., Bagniewski, P. G., Walker, D. L., Rubin, J., Goldberg, R. M., et al. (1999) · PubMed · Cited by 101 · see citing works
Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates
Han, T. H., & Zhao, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058586 · Cited by 100 · see citing works
Home monitoring in interstitial lung diseases
Wijsenbeek, M. S., Moor, C. C., Johannson, K. A., Jackson, P. D., Khor, Y. H., Kondoh, Y., Rajan, S. K., Tabaj, G. C., Varela, B. E., van der Wal, P., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00228-4 · Cited by 98 · see citing works
The oncology market for antibody–drug conjugates
do Pazo, C., Nawaz, K., & Webster, R. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00054-2 · Cited by 93 · see citing works
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
Sellmann, C., Doerner, A., Knuehl, C., Rasche, N., Sood, V. D., Krah, S., Rhiel, L., Messemer, A., Wesolowski, J. S., Schuette, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753491 · Cited by 92 · see citing works
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
Lu, D., Girish, S., Gao, Y., Wang, B., Yi, J., Guardino, E., Samant, M. K., Cobleigh, M., Rimawi, M. F., Conte, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2500-2 · Cited by 92 · see citing works
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Aoyama, M., Tada, M., Yokoo, H., Demizu, Y., & Ishii‐Watabe, A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03158-x · Cited by 89 · see citing works
Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
Chun, Y. S., Cooper, H. S., Cohen, S. J., Konski, A. A., Burtness, B. A., Denlinger, C. S., Astsaturov, I. A., Hall, M. J., & Hoffman, J. P. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2086-4 · Cited by 88 · see citing works
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Jankú, F., Han, S., Doi, T., Amatu, A., Ajani, J. A., Kuboki, Y., Cortez, A., Cellitti, S. E., Mahling, P., Subramanian, K. K., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0722 · Cited by 88 · see citing works
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
King, G. T., Eaton, K. D., Beagle, B. R., Zopf, C. J., Wong, G. Y., Krupka, H. I., Hua, S. Y., Messersmith, W. A., & El-Khoueiry, A. B. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0560-6 · Cited by 87 · see citing works
Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
Galsky, M. D., Conte, G. D., Foti, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.438 · Cited by 86 · see citing works
Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation
Simmons, J. K., Burke, P., Cochran, J. H., Pittman, P. G., & Lyon, R. P. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114932 · Cited by 84 · see citing works
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.017 · Cited by 82 · see citing works
The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
de la Torre, B. G., & Alberício, F. (2023) · Molecules · doi:10.3390/molecules28031038 · Cited by 82 · see citing works
Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation
Nilchan, N., Li, X., Pedzisa, L., Nanna, A. R., Roush, W. R., & Rader, C. M. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz009 · Cited by 80 · see citing works
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
Liao, M. Z., Lu, D., Kågedal, M., Miles, D., Samineni, D., Liu, S. N., & Li, C. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2278 · Cited by 79 · see citing works
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
Kweekel, D. M., Gelderblom, H. A. J., van der Straaten, T., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604461 · Cited by 78 · see citing works
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Boni, V., Fidler, M. J., Arkenau, H., Spira, A., Meric‐Bernstam, F., Uboha, N., Sanborn, R. E., Sweis, R. F., LoRusso, P. M., Nagasaka, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3656 · Cited by 76 · see citing works
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells
Bauzon, M., Drake, P. M., Barfield, R. M., Cornali, B. M., Rupniewski, I., & Rabuka, D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1565859 · Cited by 76 · see citing works
Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy
Bordeau, B. M., Yang, Y., & Balthasar, J. P. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3822 · Cited by 75 · see citing works
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology
Matsuda, Y., & Mendelsohn, B. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1846714 · Cited by 74 · see citing works
Human and mouse albumin bind their respective neonatal Fc receptors differently
Nilsen, J., Bern, M., Sand, K. M. K., Grevys, A., Dalhus, B., Sandlie, I., & Andersen, J. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32817-0 · Cited by 74 · see citing works
Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry
Hong, Y., Nam, S.-M., & Moon, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01433-6 · Cited by 74 · see citing works
Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads
Kumar, A., Kinneer, K., Masterson, L. A., Ezeadi, E., Howard, P. W., Wu, H., Gao, C., & Dimasi, N. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.043 · Cited by 71 · see citing works
Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis
Broos, C. E., Wapenaar, M., Looman, C. W. N., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02089-2017 · Cited by 68 · see citing works
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
Krop, I. E., Masuda, N., Mukohara, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.1002 · Cited by 68 · see citing works
Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer
Zhang, J., Ji, D., Shen, W., Xiao, Q., Gu, Y., O’Shaughnessy, J., & Hu, X. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0456 · Cited by 68 · see citing works
Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates
Khera, E., Dong, S., Huang, H., de Bever, L., van Delft, F. L., & Thurber, G. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0580 · Cited by 67 · see citing works
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study
Hu, Y., Zu, C., Zhang, M., Wei, G., Li, W., Fu, S., Hong, R., Zhou, L., Wu, W., Cui, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102010 · Cited by 67 · see citing works
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
Yin, O. Q. P., Xiong, Y., Endo, S., Yoshihara, K., Garimella, T. S., Abutarif, M. A., Wada, R., & LaCreta, F. P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2096 · Cited by 65 · see citing works
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
Jhaveri, K. L., Han, H. S., Dotan, E., Oh, D.-Y., Ferrario, C., Tolcher, A. W., Lee, K.-W., Liao, C.-Y. A., Kang, Y.-K., Kim, Y. H., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.589 · Cited by 61 · see citing works
LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Goto, K., Sang-We, K., Kubo, T., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.057 · Cited by 60 · see citing works
A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines
Coumans, R. G. E., Ariaans, G. J. A., Spijker, H. J., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00337 · Cited by 59 · see citing works
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
Zhang, J., Liu, R., Gao, S., Li, W., Chen, Y., Meng, Y., Liu, C., Jin, W., Wu, J., Wang, Y., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00522-5 · Cited by 59 · see citing works
Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape
Tarcsa, E., Guffroy, M. R., Falahatpisheh, H., Phipps, C., & Kalvass, J. C. (2020) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2020.07.002 · Cited by 58 · see citing works
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Hanna, K. S. (2019) · Drugs · doi:10.1007/s40265-019-01241-7 · Cited by 57 · see citing works
Window of opportunity studies: Do they fulfil our expectations?
Schmitz, S., Duhoux, F. P., & Machiels, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.005 · Cited by 56 · see citing works
Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability
Sussman, D. R., Westendorf, L., Meyer, D. W., Leiske, C. I., Anderson, M. E., Okeley, N. M., Alley, S. C., Lyon, R. P., Sanderson, R., Carter, P. J., et al. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzx067 · Cited by 55 · see citing works
Tissue-specific expression of IgG receptors by human macrophages ex vivo
Bruggeman, C. W., Houtzager, J., Dierdorp, B., Kers, J., Pals, S. T., Lutter, R., van Gulik, T. M., den Haan, J. M. M., van den Berg, T. K., van Bruggen, R., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223264 · Cited by 54 · see citing works
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
Martin, M., Fumoleau, P., Dewar, J. A., Albanell, J., Limentani, S. A., Campone, M., Chang, J. C., Patre, M., Strasak, A. M., de Haas, S. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw157 · Cited by 54 · see citing works
Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
Hamilton, E. P., Shapiro, C. L., Petrylak, D. P., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.sabcs20-pd3-07 · Cited by 54 · see citing works
Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Krop, I. E., Juric, D., Shimizu, T., Tolcher, A. W., Spira, A. I., Mukohara, T., Lisberg, A. E., Kogawa, T., Papadopoulos, K. P., Hamilton, E. P., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.sabcs21-gs1-05 · Cited by 51 · see citing works
Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
Chang, H., Le, H. K., & Shah, D. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041132 · Cited by 50 · see citing works
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M. D., Guardino, E., Althaus, B., Lu, D., Strasak, A. M., & ELIAS, A. D. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0691-7 · Cited by 49 · see citing works
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer
Cortés, J., Dieras, V. C., Lorenzen, S., Montemurro, F., Riera‐Knorrenschild, J., Thuss-Patience, P. C., Allegrini, G., Laurentiis, M. D., Lohrisch, C. A., Oravcova, E., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1796 · Cited by 47 · see citing works
Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers
Hamblett, K. J., Hammond, P. W., Barnscher, S. D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3914 · Cited by 46 · see citing works
Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.
Janjigian, Y. Y., Oh, D., Rha, S. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.295 · Cited by 46 · see citing works
Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index
Shao, T., Chen, T., Chen, Y., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00247-y · Cited by 45 · see citing works
166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
Schmid, P., Jung, K. H., Wysocki, P. J., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.185 · Cited by 45 · see citing works
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
Waks, A. G., Keenan, T. E., Li, T., Tayob, N., Wulf, G. M., Richardson, E. T., Attaya, V., Anderson, L., Mittendorf, E. A., Overmoyer, B. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005119 · Cited by 45 · see citing works
Self-citation
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
Antonarelli, G., Giugliano, F., Corti, C., Repetto, M., Tarantino, P., & Curigliano, G. (2021) · Pharmaceuticals · doi:10.3390/ph14090884 · Cited by 44 · see citing works
Self-citation
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Santin, A. D., Vergote, I. B., González-Martı́n, A., Moore, K. N., Oaknin, A., Romero, I., Diab, S., Copeland, L. J., Monk, B. J., Coleman, R. L., et al. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003927 · Cited by 44 · see citing works
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
Wakui, H., Yamamoto, N., Nakamichi, S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2375-2 · Cited by 43 · see citing works
Tissue-Specific Fc γ and Complement Receptor Expression by Alveolar Macrophages Determines Relative Importance of IgG and Complement in Promoting Phagocytosis of Pseudomonas aeruginosa
Berger, M., Norvell, T. M., Tosi, M. F., et al. (1994) · Pediatric Research · doi:10.1203/00006450-199401000-00015 · Cited by 41 · see citing works
Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
Lü, D., Gillespie, W., Girish, S., et al. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12192 · Cited by 41 · see citing works
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
Iveson, T. J., Sobrero, A. F., Yoshino, T., Sougklakos, I., Ou, F., Meyers, J. P., Shi, Q., Saunders, M. P., Labianca, R., Yamanaka, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3501 · Cited by 41 · see citing works
Aiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer
Tarantino, P., Curigliano, G., Parsons, H. A., Lin, N., Krop, I. E., Mittendorf, E. A., Waks, A., Winer, E. P., & Tolaney, S. M. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6597 · Cited by 41 · see citing works
Self-citation
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
Suzuki, M., Yagishita, S., Sugihara, K., Ogitani, Y., Nishikawa, T., Ohuchi, M., Teishikata, T., Jikoh, T., Yatabe, Y., Yonemori, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0397 · Cited by 40 · see citing works
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
Hurvitz, S. A., Wang, L. S., Chan, D. W., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps623 · Cited by 40 · see citing works
Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
Schettini, F., Barbao, P., Brasó‐Maristany, F., Galván, P., Martínez, D., Paré, L., Placido, S. D., Prat, A., & Guedan, S. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100102 · Cited by 39 · see citing works
LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
Rosenberg, J. E., Milowsky, M. I., Ramamurthy, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.079 · Cited by 39 · see citing works
Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Bordeau, B. M., Nguyen, T. D., Polli, J. R., Chen, P., & Balthasar, J. P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0440 · Cited by 37 · see citing works
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
Jiang, Z., Sun, T., Wang, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.1102 · Cited by 37 · see citing works
Early Clinical Study of an Intermittent Schedule for Maytansine (NSC-153858): Brief Communication 2
Eagan, R. T., Ingle, J. N., Rubin, J., Frytak, S., & Moertel, C. G. (1978) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/60.1.93 · Cited by 36 · see citing works
TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
Grivas, P. D., Pouessel, D., Park, C. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.434 · Cited by 36 · see citing works
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
Spring, L. M., Tolaney, S. M., Desai, N. V., Fell, G. G., Trippa, L., Comander, A. H., Mulvey, T. M., McLaughlin, S., Ryan, P. K., Rosenstock, A. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.512 · Cited by 34 · see citing works
Self-citation
Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
Fu, Z., Liu, J., Li, S., Chen, S., & Zhang, Y. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101795 · Cited by 34 · see citing works
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
Spring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 33 · see citing works
Self-citation
Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review
Matheson, J., Zhou, X. M. M., Bourgault, Z., & Foll, B. L. (2021) · Pharmaceuticals · doi:10.3390/ph14121316 · Cited by 33 · see citing works
FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
Świderska, K. W., Szlachcic, A., Opaliński, Ł., Zakrzewska, M., & Otlewski, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072098 · Cited by 32 · see citing works
Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry
Moor, C. C., van den Berg, C. A. L., Visser, L., Aerts, J. G. J. V., Cottin, V., & Wijsenbeek, M. S. (2020) · ERJ Open Research · doi:10.1183/23120541.00054-2020 · Cited by 31 · see citing works
58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
Marmé, F., Hanusch, C. A., Furlanetto, J., Morris, P. G., Link, T., Denkert, C., Fasching, P. A., Jackisch, C., Antolín, S., Solbach, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.074 · Cited by 30 · see citing works
Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study
Schmid, P., Wysocki, P. J., Park, Y. H., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.sabcs22-pd11-08 · Cited by 30 · see citing works
Abstract 4914: Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses
Cao, A., Heiser, R. A., Law, C., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4914 · Cited by 29 · see citing works
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
Kan, S., Koido, S., Okamoto, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1772-1 · Cited by 29 · see citing works
Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment
Shastri, P. N., Zhu, J., Skidmore, L. K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0692 · Cited by 29 · see citing works
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
Scribner, J. A., Hicks, S. W., Sinkevicius, K. W., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0915 · Cited by 27 · see citing works
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.
Petrylak, D. P., Flaig, T. W., Mar, N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.435 · Cited by 26 · see citing works
Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates
Hasan, M. M., Laws, M., Jin, P., et al. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.015 · Cited by 25 · see citing works
Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues
Zhou, Q., Kyazike, J., Boudanova, E., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14070672 · Cited by 25 · see citing works
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
André, F., Hamilton, E. P., Loi, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.3025 · Cited by 25 · see citing works
Hydrophilic Sequence-Defined Cross-Linkers for Antibody–Drug Conjugates
Walker, J. A., Sorkin, M. R., Ledesma, F., Kabaria, S. R., Barfield, R. M., Rabuka, D., & Alabi, C. A. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00713 · Cited by 22 · see citing works
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistancePreprint
Yamazaki, C. M., Yamaguchi, A., Anami, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423326 · Cited by 22 · see citing works
Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation
Bardia, A., Coates, J. T. T., Spring, L. M., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-2638 · Cited by 22 · see citing works
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope
Yamaguchi, A., Anami, Y., Ha, S. Y. Y., Roeder, T. J., Xiong, W., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116013 · Cited by 20 · see citing works
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
Gibiansky, L. V., Passey, C., Voellinger, J. L., Gunawan, R., Hanley, W. D., Gupta, M., & Winter, H. R. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12850 · Cited by 20 · see citing works
MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Levy, B., Paz-Ares, L., Rixe, O., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.152 · Cited by 19 · see citing works
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Barroso‐Sousa, R., Tarantino, P., Tayob, N., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00385-2 · Cited by 17 · see citing works
Self-citation
Transient Inhibition of Trastuzumab–Tumor Binding to Overcome the “Binding-Site Barrier” and Improve the Efficacy of a Trastuzumab–Gelonin Immunotoxin
Chen, P., Bordeau, B. M., Zhang, Y., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0192 · Cited by 14 · see citing works
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Prat, A., Falato, C., Brunet, L. P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.279 · Cited by 11 · see citing works
Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors.
Tang, M. T. C., Garg, A., Bonate, P. L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.568 · Cited by 7 · see citing works
Effect of Ado-Trastuzumab Emtansine on Autologous Platelet Kinetics and Function
Ansary, A. M., Stolla, M., Corson, J., Cundy, A., Bailey, S. L., Pellham, E., Bawcom-Randall, M., Slichter, S. J., & Gadi, V. K. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00237 · Cited by 7 · see citing works
Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy
Shang, C., Yang, L., Zhang, J., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-4256 · Cited by 6 · see citing works
605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
Moore, K. N., Lorusso, D., Oaknin, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.733 · Cited by 5 · see citing works
Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)
Tarantino, P., Tayob, N., Dang, C. T., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.sabcs22-pd18-01 · Cited by 4 · see citing works
Self-citation
Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Colombo, R., Barnscher, S. D., & Rich, J. R. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-1538 · Cited by 3 · see citing works
Abstract 4263: A novel pegylated biparatopic antibody-drug conjugate (pb-adc) targeting cancers with low HER2+ expression
Liu, S., Yin, S., Lyu, W., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-4263 · Cited by 2 · see citing works
Abstract 965: Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma
Tarantino, G., Ricker, C. A., Wang, A., Ge, W. H., Huang, A. Y., Madha, S., Chen, J., Shi, Y., Frederick, D. T., Freeman, S. S., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-965 · Cited by 2 · see citing works
Untitled work
Segaloff (1980) · doi:10.1002/1097-0142(19800901)46:5

Flagged first, then by citations

Sorted by citations

Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659 · see citing works
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254 · see citing works
Self-citation
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · see citing works
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20 · see citing works
Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future
Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100032 · Cited by 14 · see citing works
Self-citation

Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
García‐Azorín, D., Martínez, B., Gutiérrez, M., et al. (2022) · Toxins · doi:10.3390/toxins14120850 · Cited by 5 · see citing works
Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies
Stanulović, V., Hodolič, M., Mitsikostas, D. D., & Papadopoulos, D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15016 · Cited by 43 · see citing works
Tolerability of topical antimicrobials in treatment of acne vulgaris.
Bartlett, K. B., Davis, S. A., & Feldman, S. R. (2014) · PubMed · Cited by 5 · see citing works
TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS
Khamaganova, I. V. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-20-166-170
Tolerability of combined treatment with lithium and fluoxetine
Hawley, C. J., Roberts, A. G., & Baldwin, D. S. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400910-00005 · Cited by 26 · see citing works

Authors: Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M.
Affiliations: Harvard University (US)
United States Food and Drug Administration (US)
Corresponding author: Tolaney, Sara M.
ORCID: Tarantino, Paolo
Ricciuti, Biagio
Pradhan, Shan M.
Tolaney, Sara M.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2023-06-09
Volume: 20
Issue: 8
Pages: 558-576
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/s41571-023-00783-w
OpenAlex: W4379986466
Cited by: 269
References: 200
Citations by year: 2026: 86 · 2025: 89 · 2024: 76 · 2023: 18
FWCI: 11.33
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: antibody-drug conjugates, solid tumors, drug toxicity, off-target toxicity, on-target toxicity, predictive biomarkers, dose optimization, treatment schedule, early-stage cancer, combination therapy, therapeutic index
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks